Jie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jie Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Hao Xu
National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication - Jingen Li
Dongzhimen Hospital, Beijing University of Chinese Medicine
1 shared publication - Lijing Zhang
Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
1 shared publication - Naima Covassin
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, USA
1 shared publication - Virend K. Somers
Mayo Clinic
1 shared publication
Latest Publications
- Open Access
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e032527
Trends and Disparities in Treatment and Control of Atherosclerotic Cardiovascular Disease in US Adults, 1999 to 2018
Background: Although cardiovascular mortality continued declining from 2000 to 2019, the rate of this decrease decelerated. We aimed to assess the trends and disparities in risk factor control and treatment among US adults with atherosclerotic cardiovascular disease to find potential causes of the deceleration. Methods and Results: A total of 55 ,021 participants, aged ≥20 years, from the 1999 to 2018 National Health and Nutrition Examination Survey were included, of which 5717 were with atherosclerotic cardiovascular disease. Risk factor control was defined as hemoglobin A1c P trend ≤0.001). Non–high‐density lipoprotein cholesterol P trend P joinpoint =0.14). Similarly, the proportion of participants achieving hemoglobin A1c control began to decrease after 2006 ( P joinpoint =0.05, P trend =0.001). The percentage of participants achieving all 3 targets increased significantly from 4.5% to 18.6% across 1999 to 2018 ( P trend =0.02), but the increasing trend decelerated after 2005 to 2006 ( P joinpoint <0.001). Striking disparities in risk factor control and medication use persisted between sexes, and between different racial and ethnic populations. Conclusions: Worsened control of glycemia, blood pressure, obesity, and alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may be contributing factors to the observed deceleration in decreasing cardiovascular mortality trends.
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e032527
Open AccessTrends and Disparities in Treatment and Control of Atherosclerotic Cardiovascular Disease in US Adults, 1999 to 2018
Background: Although cardiovascular mortality continued declining from 2000 to 2019, the rate of this decrease decelerated. We aimed to assess the trends and disparities in risk factor control and treatment among US adults with atherosclerotic cardiovascular disease to find potential causes of the deceleration. Methods and Results: A total of 55 ,021 participants, aged ≥20 years, from the 1999 to 2018 National Health and Nutrition Examination Survey were included, of which 5717 were with atherosclerotic cardiovascular disease. Risk factor control was defined as hemoglobin A1c P trend ≤0.001). Non–high‐density lipoprotein cholesterol P trend P joinpoint =0.14). Similarly, the proportion of participants achieving hemoglobin A1c control began to decrease after 2006 ( P joinpoint =0.05, P trend =0.001). The percentage of participants achieving all 3 targets increased significantly from 4.5% to 18.6% across 1999 to 2018 ( P trend =0.02), but the increasing trend decelerated after 2005 to 2006 ( P joinpoint <0.001). Striking disparities in risk factor control and medication use persisted between sexes, and between different racial and ethnic populations. Conclusions: Worsened control of glycemia, blood pressure, obesity, and alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may be contributing factors to the observed deceleration in decreasing cardiovascular mortality trends.